NCT03444844View on ClinicalTrials.gov

Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 10, 2018

Primary Completion Date

October 27, 2020

Study Completion Date

July 31, 2022

Conditions
Prostate Cancer RecurrentProstate Cancer
Interventions
DRUG

Ga-68 P16-093 PET/CT scan

IV injection followed by PET/CT scanning

Trial Locations (1)

46202

Goodman Hall, Indiana Institute for Biomedical Imaging Sciences, Indiana University School of Medicine, Indianapolis

All Listed Sponsors
collaborator

Indiana University

OTHER

lead

Five Eleven Pharma, Inc.

INDUSTRY

NCT03444844 - Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer | Biotech Hunter | Biotech Hunter